Business Context and Reporting Period
Company: Donaldson Company, Inc. (DCI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended October 31, 2025 (Fiscal Q1 2026)
Business Overview: A global leader in technology-led filtration products and solutions serving Mobile Solutions, Industrial Solutions, and Life Sciences markets.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $935.4 | $900.1 |
| Gross Profit | $328.8 | $319.6 |
| Gross Margin | 35.2% | 35.5% |
| Operating Income | $149.3 | $130.8 |
| Operating Margin | 16.0% | 14.5% |
| Net Earnings | $113.9 | $99.0 |
| Diluted EPS | $0.97 | $0.81 |
| Operating Cash Flow | $125.4 | $72.9 |
| Cash and Equivalents (End of Period) | $210.7 | $221.2 |
| Total Debt (Short-term + Long-term) | $681.0 | N/A |
Note: Total Debt calculated as Short-term borrowings ($2.5M) + Current maturities of long-term debt ($6.5M) + Long-term debt ($671.5M).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3.9% ($35.3M) driven by pricing benefits (+$15.9M), favorable foreign currency translation (+$11.9M), and volume growth (+$7.5M).
- Profitability: Net earnings rose 15.1% to $113.9M. Operating income increased 14.1% to $149.3M, aided by a $9.3M gain on the sale of fixed assets (land and building) related to footprint optimization.
- Segment Performance:
- Mobile Solutions: Sales up 4.5% to $598.3M; earnings before tax up to $111.3M. Aftermarket sales grew significantly due to market share gains.
- Industrial Solutions: Sales flat (+0.1%); earnings before tax declined 21.5% to $32.2M due to unfavorable mix and higher operational costs.
- Life Sciences: Sales up 13.1% to $79.3M; returned to profitability with $7.3M earnings before tax (vs. $5.3M loss prior year) driven by restructuring benefits and volume leverage.
- Cash Flow: Operating cash flow improved significantly by $52.5M to $125.4M, primarily due to reduced working capital requirements. Investing cash outflows decreased by $92.6M as the prior year included a $71.0M equity investment in Medica.
- Capital Allocation: The company repurchased 1.2 million shares for $91.9M and paid dividends of $34.7M.
Guidance, Outlook, and Risks
- Tariff Impact: Management expects annual costs from recently implemented tariffs to be approximately $25 million (revised down from $35 million), representing less than 1% of total sales. These costs are expected to be largely offset by pricing increases.
- Restructuring: The company continues global footprint and cost optimization actions. Future costs associated with these actions through fiscal 2026 are estimated between $5.0 million and $10.0 million.
- Market Risks: Key risks include global economic conditions, geopolitical tensions, supply chain disruptions, and potential new tariffs on imports from Mexico, China, and the EU. The company notes that a weaker U.S. dollar positively impacted international sales and earnings in this quarter.
- Debt Covenants: The company remains in compliance with all financial covenants related to interest coverage and leverage ratios.
Investor Verification Checklist
- Tariff Mitigation: Verify the ability to pass through the estimated $25M annual tariff cost to customers without significant volume erosion.
- One-Time Gains: Assess the sustainability of operating margins excluding the $9.3M gain on sale of fixed assets.
- Industrial Segment Margins: Monitor the Industrial Solutions segment for continued margin pressure due to mix shifts and operational costs.
- Working Capital Trends: Confirm if the improvement in operating cash flow (driven by working capital) is sustainable or a one-time benefit.
- Share Repurchase Runway: Note that $4.7 million shares remain authorized for repurchase under the current plan.